Verucerfont

InvivoChem Cat #:V3636CAS #:885220-61-1 Purity >=98%

Description: Verucerfont (also known as GSK561679 and NBI77860) is a novel and potent antagonist of corticotropin-releasing factor receptor 1 (CRF1) with IC50s of ca.6.1, > 1000 and > 1000?nM for CRF1, CRF2, and CRF-BP, respectively. Blockade of corticotropin-releasing factor receptor 1 (CRF1) suppresses stress-induced alcohol seeking in rodents, but clinical translation remains. Verucerfont blocks the CRH-1 receptor, and so reduces ACTH release following chronic stress. It is under investigation as a potential treatment for alcoholism, as chronic stress is often a factor in both development of alcoholism and relapse in recovering alcoholics. It has shown promising results in animal studies but has not been tested in humans.

References: Neuropsychopharmacology. 2016 Nov; 41(12):2818-2829.

-20C for 3 years in powder form

Synonym: NBI77860; NBI-77860; NBI 77860; GSK561679; GSK-561679; GSK 561679; SK-561, 679; GSK561679A; Verucerfont.
Chemical Name: (S)-3-(4-methoxy-2-methylphenyl)-2, 5-dimethyl-N-(1-(3-methyl-1, 2, 4-oxadiazol-5-yl)propyl)pyrazolo[1, 5-a]pyrimidin-7-amine
InChi Key: VKHVAUKFLBBZFJ-SFHVURJKSA-N
InChi Code: InChI=1S/C22H26N6O2/c1-7-18(22-24-15(5)27-30-22)25-19-11-13(3)23-21-20(14(4)26-28(19)21)17-9-8-16(29-6)10-12(17)2/h8-11, 18, 25H, 7H2, 1-6H3/t18-/m0/s1
SMILES Code: CC[CH](NC1=CC(C)=NC2=C(C3=CC=C(OC)C=C3C)C(C)=NN12)C4=NC(C)=NO4